upplementary Doctors' Guide
esidential Care Home Vaccination Programme 2019/20
easles Vaccination Mop-up Programme r Healthcare Workers of Residential Care Home for Persons with Disabilities and Residential nild Care Centres

Table of Contents

1. In	troductiontroduction	. 4
1.1.	What is Measles Vaccination Mop-up Programme for Healthcare Workers under Residential Care Home Vaccination Programme 2019/20?	
me n	Residential Care Home vaccination Frogramme 2019/20:	.4
1.2.	Vaccination period	.4
1.3.	Eligibility for measles vaccination under the mop-up programme	.4
1.4.	Information of measles and measles vaccines	5
2. Ad	lministrative arrangement under the measles vaccination mop-up	
progra	amme1	11
2.1.	Arranging MMR vaccination date(s) in RCHDs and RCCCs	11
2.2.	Obtaining MMR consent and checking eligibility	11
2.3.	Vaccine ordering & vaccine storage	12
3. Fo	orms and documents1	14
3.1.	MMR Vaccination Consent Form	14
3.2.	Screening Questionnaire for MMR Vaccination for HCWs of RCHD and RCCC1	15

List of Acronyms

CHP Centre for Health Protection

DH Department of Health

eHS(S) eHealth System (Subsidies)

HCWs Healthcare Workers

ImmD Immigration Department

MCHK Medical Council of Hong Kong MMR Measles, Mumps and Rubella

PMVD Programme Management and Vaccination Division

RCCC Residential Child Care Centre

RCH Residential Care Home

RCHD Residential Care Home for Persons with Disabilities

RVP Residential Care Home Vaccination Programme

SCVPD Scientific Committee on Vaccine Preventable Diseases

VMO Visiting Medical Officer

1. Introduction

1.1. What is Measles Vaccination Mop-up Programme for Healthcare Workers under the Residential Care Home Vaccination Programme 2019/20?

The measles vaccination mop-up programme is launched making reference to the guiding principles formulated by the Scientific Committee on Vaccine Preventable Diseases (SCVPD) under the Centre for Health Protection. It aims to further boost up the herd immunity against measles in the community.

Under the Residential Care Home Vaccination Programme (RVP) 2019/20, free measles vaccination will be provided to eligible healthcare workers (HCWs) in:

- 1. Residential Care Homes for Persons with Disabilities (RCHDs), and
- 2. Residential Child Care Centres (RCCCs).

The aforementioned HCWs who are non-immune to measles are advised to receive measles vaccination, given their close contact to children and persons with disability who are vulnerable groups for measles infection and serious complication. Measles vaccination will be delivered by Visiting Medical Officers (VMOs) to eligible HCWs under the one-off mop-up programme.

Private doctors invited by RCHD/RCCC can enroll in the RVP as VMOs. An injection fee of \$100 per dose will be reimbursed to VMO and VMO is prohibited to charge any fee from the clients or share any injection fee with RCHDs/RCCCs, incharges of RCHDs/RCCCs or recipients.

1.2. Vaccination period

The measles vaccination mop-up programme will start **from 23 October 2019** until stocks of vaccines supplied by the Government expire in September 2020.

1.3. Eligibility for measles vaccination under the mop-up programme

All HCWs of RCHDs and RCCCs born in 1967 or after and fulfil ALL the following three criteria are eligible to receive two doses* of Measles, Mumps and

Rubella (MMR) vaccine under RVP 2019/20.

- I. Did not have laboratory evidence of immunity (i.e. no laboratory test ever done or tested negative/indeterminate for measles immunoglobulin G);
- II. Did not have laboratory confirmed measles infection in the past; AND
- III. Have never been vaccinated with two doses of measles-containing vaccine or have unknown vaccination status.

*Only <u>one dose</u> of MMR vaccine is required for those who had already received one dose of measles vaccination in the past.

They should also hold a valid Hong Kong Identity Card or Certificate of Exemption (please refer to RVP Doctor's Guide - Annex A for samples of identity documents).

To screen and determine the eligibility for receiving MMR vaccine, health assessment forms (screening questionnaires) will be distributed to HCWs of RCHDs/RCCCs. VMOs are responsible to collect the screening questionnaires together with the MMR vaccination consent forms for checking before vaccination day.

1.4. Information of measles and measles vaccines

Under the measles vaccination mop-up programme, the Government provides MMR vaccine to eligible HCWs of RCHDs and RCCCs. The MMR vaccine is the main measles-containing vaccine provided in Hong Kong, and it can effectively prevent three infectious diseases, namely measles, mumps and rubella.

1.4.1. Measles

Measles is caused by the measles virus and spreads through the air, by droplet or direct contact with nasal or throat secretions from infected persons, and less commonly, by articles soiled with nose and throat secretions. Affected persons will present initially with tiredness, fever, cough, red eyes and white spots inside the mouth. This is followed by a red blotchy skin rash 3 to 7 days later, which usually spreads from the face down to the rest of the body. In severe cases, middle ear, lungs and brain can get involved and lead to serious consequences or even death. Measles infection in pregnancy can result in adverse pregnancy outcomes, including

pregnancy loss, preterm birth and low birth weight. Vaccination against measles is the most effective preventive measure.

Please refer to the CHP website (www.chp.gov.hk/en/healthtopics/content/24/31.html) for further information about the disease.

1.4.2. MMR Vaccine

The MMR vaccine is an attenuated live virus vaccine and it can be given at the same time with other live vaccines or separated by an interval of **at least four weeks**.

HCWs who are eligible to receive two doses of MMR vaccine should receive them separated by an interval of **at least four weeks**.

- I. The following individuals should NOT receive MMR vaccine or should wait
- (a) Pregnancy: Women should avoid pregnancy for three months after vaccination and take appropriate contraceptive measure
- (b) Serious allergic reaction to a previous dose of MMR vaccine
- (c) Known history of severe allergy to any vaccine component (e.g. gelatin or neomycin)
- (d) Individuals with severe immunosuppression from diseases or treatment (e.g. on current cancer treatment such as chemotherapy and radiotherapy, taking immunosuppressive medicines such as high dose corticosteroid, etc.)
- (e) Has received immunoglobulin or other blood products (e.g. blood transfusion) within the past 11 months
- (f) Has received other live-attenuated vaccines in the past four weeks
- (g) Fever or any illnesses on the day of vaccination
- (h) Person with severe allergic reaction (e.g. anaphylaxis) to eggs should consult a healthcare professional for vaccination in an appropriate setting

II. Side effects

Possible reactions after MMR vaccination (e.g. fever, rash, etc,) are in general mild and transient. There is a 1 in 3 million chance of developing encephalitis or meningitis after receiving MMR vaccine, but this does not usually have long-lasting adverse effects after recovery.

III. Instructions for use of MMR vaccine

The Department of Health (DH) would supply and deliver the MMR vaccines (Figure. 1) together with needles and syringes (Figure. 2) required for vaccination to the RCHD/RCCC. The packaging of MMR vaccine is labelled with Spanish instructions for use with diluent in vial instead of prefilled syringe. English instructions for use per pack of MMR vaccines will be provided. Please refer to the instructions on reconstitution prior to preparation and vaccination.

M-M-R II

- One single-dose vial of MMR lyophilized vaccine +
 One single-dose vial of diluent
- ♦ Needles and syringes for reconstitution and injection are separately provided
- ❖ The "Measles, Mumps and Rubella Vaccines" (MMR vaccine) used in the Mop-up Programme were procured by the Government of the HKSAR from one of the suppliers of registered MMR vaccines in Hong Kong, Merck Sharp & Dohme (Asia) Ltd (MSD). As this batch of vaccines was originally not intended for supply to Hong Kong, the packing are only labelled in Spanish. Nonetheless, they were manufactured by the same manufacturer with the same master formula (including gelatin originated from porcine skin collagen as one of the inactive ingredients) and finished product specifications as the MMR vaccine registered in Hong Kong by MSD.

All doctors are advised to read carefully the product information of the vaccines, noting especially the vaccine components, contraindications, route of administration, dosage for eligible recipients, storage and handling. Vaccine name and expiry date should also be checked immediately prior to vaccination.

Figure 1.) Sample of M-M-R II vaccines supplied by the DH







Figure 2.) Syringes for reconstitution and injection



♦ Procedural steps for reconstitution of MMR vaccine

- 1. Perform hand hygiene before handling of MMR vaccines.
- 2. Take out one diluent vial (gray cap) and one lyophilized vaccine vial (blue cap) from their respective cartons.
 - (Use the diluent provided by the manufacturer for reconstitution)
- 3. Remove the plastic cap (gray color) of the diluent vial.
- 4. Use a 3ml syringe to withdraw the entire volume of diluent in the vial (gray cap) for reconstitution.
- 5. Remove the plastic cap (blue color) of the lyophilized vaccine vial.
- 6. Inject all the diluent in the syringe into the vial of lyophilized vaccine (blue cap). Discard the used 3ml syringe into sharps box.
- 7. Swirl the lyophilized vaccine vial (blue cap) thoroughly to dissolve the entire content as a clear yellow solution.
 - (If the lyophilized vaccine cannot be dissolved, discard)
- 8. Use a 1ml syringe to withdraw the entire reconstituted content from the lyophilized vaccine vial (blue cap). Ensure the needle is tightly attached to the hub of syringe before withdrawal of the reconstituted vaccine.
- 9. Inject the total volume of the dissolved content of reconstituted vaccine subcutaneously.
- 10. After vaccination, discard the used syringes into the sharps box and perform hand hygiene.
- * It is recommended that the vaccine be used as soon as possible after reconstitution.
- *Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. M-M-R II when reconstituted is clear yellow.
- *It is important to use a separate sterile syringe and needle for each individual patient to prevent transmission of hepatitis B and other infectious agents from one person to another.

♦ Dosage & Route of administration

Dosage

0.5ml for any age

Route of administration

Subcutaneous injection only, preferably into the outer aspect of the upper arm. Please use the 1ml syringe supplied by the DH for injection.

For more details on vaccination and injection techniques, please refer to Section 3.4 of the Hong Kong Reference Framework for Preventive Care for Children in Primary Care Settings - Module on Immunisation.

(www.pco.gov.hk/english/resource/files/Module_on_Immunisation_Children.pdf)

2. Administrative arrangement under the measles vaccination mop-

up programme

As vaccination is invasive in nature and the procedure is performed under non-clinic setting, VMO should give due consideration to safety and liability issues when providing vaccination service in RCHDs and RCCCs setting. The following notes aim to highlight areas that VMO should consider or note when providing vaccination service to eligible HCWs under the mop-up programme in non-clinic setting.

Please note that the supplementary guidebook mainly highlights the specific administrative arrangements related to MMR vaccination required under the mop-up programme. Please refer to VMO's guidebook under RVP 2019/20 for details.

2.1. Arranging MMR vaccination date(s) in RCHDs and RCCCs

- (a) Confirm the date and time of MMR vaccination with in-charge of RCHD/RCCC.
- (b) HCWs could receive seasonal influenza vaccination (SIV) and MMR vaccination on the same day, with vaccines administered in separate sites of the body with different syringes (Left arm: SIV; Right arm: MMR).
- (c) HCWs who are eligible to receive **two doses of MMR vaccine** should be given separately by **an interval of at least four weeks**. VMO should liaise with RCHD/RCCC to arrange the date of second dose of MMR vaccination.

2.2. Obtaining MMR consent and checking eligibility

- (a) MMR consent forms and health assessment forms (screening questionnaires) will be distributed to HCWs of RCHDs/RCCCs. VMOs are responsible to collect original or copies of duly completed MMR Vaccination Consent Form and screening questionnaire from RCHD/RCCC at least 20 working days before vaccination day.
 - i. Check that the HCW of RCHD/RCCC has completed the screening questionnaire for MMR vaccination.
 - ii. Screen if there are any contraindications or precautions to the MMR vaccine.
 - iii. Determine whether the HCW is eligible for MMR vaccination. Check

- together with the documentation proof if any (i.e. vaccination card(s) and/or laboratory records).
- iv. Check that the HCW has completed the consent form for MMR vaccination and signed in Part B of the consent form.
- v. If irregularities are found on the consent form, verify with the RCHDs and RCCCs for correct information. If a duly-completed consent form and screening questionnaire cannot be checked before vaccination, vaccination for that particular person should be deferred until checking is in order.
- vi. Verify the eligible HCW's past vaccination history and vaccination records in the eHS(S) and decide whether vaccination is needed.
- vii. If vaccination record and eligibility status of the person have not been checked in the eHS(S), the vaccination should be deferred until checking of eligibility status is in order.
- viii. Vaccination is only applicable if there is available vaccination quota for the eligible HCWs and he/she is clinically indicated for MMR vaccination. Vaccination fee will not be reimbursed if vaccination is provided to an ineligible person or to an eligible person who has no available vaccine quota.

2.3. Vaccine ordering & vaccine storage

According to the Pharmacy and Poisons Ordinance (Cap.138), vaccines should be prescribed by the doctor. VMOs are responsible for pre-ordering sufficient vaccines for consented persons and ensure the vaccines ordered are properly stored under RVP.

(1) Vaccine Ordering for MMR vaccine

- a) Liaise with RCHDs/RCCCs to confirm:
 - (i) vaccination date:
 - (ii) number of MMR vaccines required;
 - (iii) the place for proper vaccine storage;
 - (iv) vaccine delivery arrangement (i.e. delivery date, time and designated staff to receive vaccines).
- b) Submit vaccine order request to PMVD by VMO <u>at least 10 working days</u> before vaccination. VMO should refer to the number of eligible persons to decide the quantity of vaccines required.

c) PMVD will contact VMO to confirm the number of vaccines required, delivery date and address with the corresponding RCHD/RCCC. Contact PMVD if VMO cannot receive order confirmation 3 working days after order submission.

(2) Vaccine storage and cold chain maintenance for MMR vaccine

- a) Check to ensure that vaccines are ready and properly stored in RCHD/RCCC. As MMR vaccine is a live-attenuated vaccine, **cold chain** should be strictly maintained.
- b) Breach in the cold chain will render the vaccine effectiveness. Please follow the guidelines for proper vaccine storage and handling as set out in Section 3.3 of the Hong Kong Reference Framework for Preventive Care for Children in Primary Care Settings Module on Immunisation:

 (http://www.pco.gov.hk/english/resource/files/Module_on_Immunisation_Ch_ildren.pdf). Please pay particular attention to the following points:
 - (i) strictly follow the vaccine manufacturers' recommendation on storage of individual vaccines;
 - (ii) purpose-built vaccine refrigerators (PBVRs) are the preferred means of storage for vaccines;
 - (iii) cyclic defrost and bar refrigerators are not recommended because they produce wide fluctuations in the internal temperatures and regular internal heating;
 - (iv) the empty shelves, floors, drawers and the door should be filled with plastic water bottles or containers to maintain temperature stability if not using a PBVR. Leave a small space between the bottles or containers;
 - (v) the temperature of the vaccine fridge should be monitored by a data logger or maximum-minimum thermometer;
 - (vi) the maximum and minimum temperatures of the vaccine storage unit should be checked and recorded regularly (at least twice daily) onto a temperature log sheet, to maintain under cold chain at 2-8°C before administration of vaccines;
- c) In case of temperature excursion (i.e. if vaccines have been exposed to temperatures outside the recommended range), check whether the in-charge of RCHD/RCCC has informed PMVD as appropriate. PMVD will contact the manufacturer or drug company to evaluate the stability/effectiveness of the affected vaccines and determine whether they are still serviceable. Please do not use the affected vaccines until receiving confirmation from PMVD.

3. Forms and documents

RCH/RCCC Code

(To be completed by RCH)

3.1. MMR Vaccination Consent Form

		(HP D	epartmen	t of Health	Ť	1. TR 2. TR		
	Resid			Vaccination 1		Type of in 2019/20		
				Consent Form		Vaccines* (DD/MM/YY)		
	for M			ıbella (MMR)	Vaccination	MMR (1 st) / / MMR (2 nd) / /		
under Measles Vaccination Mop-up Programme Name of VMO:								
						Signature of VMO:		
2. Duly co days pri 3. This for	mpleted and for to vaccin m is to be re	I signed con ation for che tained by th	sent form sho ecking vaccina e VMO after v	tion record of the vaccination.	g Medical Offic recipient.	eer (VMO) <u>at least 20 workin</u>		
Part A Persona	al Particula	ars of the l	Recipient (as	stated on the id	entity docum	ent)		
Name				(English)		(Chinese)		
Date of Birth	dd	mm	уууу		Sex	Male Female		
Hong Kong Identity	Card No.				Date of Issue	dd mm yyyy		
Chinese Commercia (if applicable)	al Code							
Rank:				Contact Tel. N	Vo.:			
Part B Underta	king and E	Declaration	1	<u> </u>				
To Be Completed	by the Re	cipient						
I am a staff of resid Measles, Mumps &				sabilities / reside	ntial child care	e centre. I consent to receive		
I have read the appended Information about MMR Vaccination, Undertaking and Declaration and Statement of Purpose of Collection of Personal Data and consent to receive MMR vaccine provided by the Government.								
I understand I shoul	d avoid preg	nancy for th	ree months af	ter MMR vaccina	tion. (For wo	men only)		
form and any inform the "Statement of Po	nation provi urpose" of C	ded to healt Collection of	h care profess Personal Data	ional for the use a. I note that the	by the Govern Department o	y personal data in this consen- ment for the purpose set out in f Health may contact me or the yself has received the MMF		
	he Governm					g Kong Special Administrative of the Courts of Hong Kong		
I have read this cons	sent form car	refully and f	fully understoo	d my obligations	and liability ur	nder this consent form.		
Signature of Recipie	ent			Date				
2 m 10 m :	1: 4 34	D.	1.1	4.6	HILCAD C	ne of the suppliers of registered MMI		

eHS(S) Transaction No.

² The MMR vaccine used in the Mop-up Programme were procured by the Government of the HKSAR from one of the suppliers of registered MMR vaccines in Hong Kong, Merck Sharp & Dohme (Asia) Ltd (MSD). The packing is labelled in Spanish. This batch of MMR vaccines contains gelatin originated from porcine skin collagen as one of the inactive ingredients.

3.2. Screening Questionnaire for MMR Vaccination for HCWs of

RCHD and **RCCC**

麻疹疫苗補種計劃

殘疾人士院舍及留宿幼兒中心職員

麻疹、流行性腮腺炎及德國麻疹混合疫苗(MMR疫苗)補種計劃節選問卷

請在接種 MMR 疫苗前回答以下問題,在適當的方格內加上✓。

以下任何一項答案為「是」或「有」的人士 <u>不需</u> 在是次計劃接種 MMR 疫苗 ¹								
1. 你是否已接受兩劑或以上 MMR 疫苗?	□ 是 □ (□ 一剤							
2. 你有沒有化驗證明曾感染麻疹?	□有□	沒有 🗌 不清楚						
3. 你有沒有化驗證明對麻疹已有免疫力?	□ 有 □	沒有 🗌 不清楚						
以下任何一項答案為「是」、「有」或「不清楚」的人士 <u>不應</u> 接種 MMR 疫苗								
 你有沒有試過對麻疹、流行性腮腺炎及德國麻疹混合疫苗、新霉素或明膠有嚴重敏威反應,如呼吸困難,甚至休克等症狀? 	□有□	沒有 □ 不清楚						
 你有沒有癌病、白血病、感染愛滋病病毒(HIV+),或其他免疫系 統疾病的病歷? 	□有□	沒有 □ 不清楚						
6. 你有沒有正在服用高劑量類固醇、抗癌藥或接受放射治療?	□有□	沒有 🗌 不清楚						
以下任何一項答案為「有」或「不清楚」的人士須 <u>延遲</u> 接種 MMR 疫苗。詳情請向你的家庭醫生查詢。								
7. 你正在懷孕或有機會懷孕嗎?(只適用於婦女)	□ 是/有 /[□ 不是/沒有						
	□ 不清楚							
上一次經期的第一日: (只適用於婦女)	年	月日						
	□ 已停經							
8. 你今天有沒有發燒或不適?	□有□	沒有						
9. 你在過去這十一個月內有沒有接受過輸血、血漿或免疫球蛋白?	□有□	沒有 □ 不清楚						
10. 你在過去四星期內有沒有接種過減活疫苗,例如麻疹、流行性腮腺炎、德國麻疹混合疫苗、水痘疫苗、麻疹、流行性腮腺炎、德國麻疹及水痘混合疫苗、卡介苗、日本腦炎疫苗、減活流感疫苗(噴鼻疫苗)?	□有□	沒有 □ 不清楚						
11. 你有沒有血凝固或血小板過低的疾病或問題?	□有□	沒有 🗌 不清楚						
12. 你是否曾對雞蛋產生嚴重過敏(如過敏性休克)? *答案為「是」的人士,請徵詢專業醫護人員及在適當的場所內接種。	□ 是* □	不是 □ 不清楚						

2019年8月修訂

RVP consent form for MMR 19/20

L文補權計劃所使用的MMR疫苗由香港特別行政區政府從其中一間在香港註冊MMR疫苗供應商美國默沙東藥廠有限公司(默沙東)採購。這批疫苗原先並非預計供應給香港,因此包裝上只有西班牙文的標籤說明,但一如默沙東在本港註冊的MMR疫苗,均由同一製造商以相同原版配方(當中輔料含有源自豬皮膚膠原蛋白的明膠)及製成品規格製造。